Share Twitter LinkedIn Facebook Email Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read
HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023 Small Cell Lung Cancer 2 Mins Read
Emerging Treatment for SCLC – Leading Developments & Current Questions in Lung Cancer Small Cell Lung Cancer 1 Min Read